1. Scrip
  2. >>ESG
  3. >>Diversity & Inclusion

Novartis Looks To Take Its Diversity Show On The Road

Company In Early Stages Of International Expansion

 
• By Alaric DeArment

Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.

Clinical Research diagram

Kim Fookes is only about a month into her role as global head of diversity and inclusion in clinical trials at Novartis AG, but her work to help improve clinical trial diversity – especially in the US – predates that by several months, and the company has been making efforts in that regard for multiple years. Now, Novartis is looking to take some of the lessons it has learned in the US abroad as well.

Fookes has worked for Novartis for two and a half years, joining in April 2019 from AbbVie Inc., and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 
• By Anju Ghangurde

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

More from ESG

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Why Global Pull Incentives Matter For AMR Drugs

 
• By Lisa Takagi

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 
• By Mary Jo Laffler

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.